<DOC>
	<DOCNO>NCT01901185</DOCNO>
	<brief_summary>The purpose study assess ability people rheumatoid arthritis ( RA ) psoriatic arthritis ( PsA ) use experimental autoinjector self inject etanercept ( EnbrelÂ® ) .</brief_summary>
	<brief_title>Study Evaluate Ability Subjects With Rheumatoid Arthritis Psoriatic Arthritis Effectively Use Reusable Autoinjector Self-inject Etanercept</brief_title>
	<detailed_description>Study participant need self-administering etanercept great equal 6 month prior screen . You study 9 week . This include 4-week screening period 5-week treatment period .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subject diagnosis RA PsA indicate treatment etanercept per current label , base history . Subject willing selfinject per investigator judgement screen . Subject known history tuberculosis . Latex allergy . Subject active infection ( include chronic localized infection ) antiinfectives indicate within 4 week prior first study dose etanercept . Subject prosthetic joint infection within 5 year screen native joint infection within 1 year screening . Other criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>